Lisanti Capital Growth LLC Purchases Shares of 62,415 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Lisanti Capital Growth LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 62,415 shares of the company's stock, valued at approximately $3,158,000.

Several other large investors also recently made changes to their positions in the company. Grandfield & Dodd LLC increased its stake in shares of Ionis Pharmaceuticals by 0.7% in the fourth quarter. Grandfield & Dodd LLC now owns 33,104 shares of the company's stock valued at $1,675,000 after purchasing an additional 242 shares during the period. Treasurer of the State of North Carolina increased its stake in shares of Ionis Pharmaceuticals by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 62,532 shares of the company's stock valued at $2,836,000 after purchasing an additional 310 shares during the period. Victory Capital Management Inc. increased its stake in shares of Ionis Pharmaceuticals by 2.3% in the third quarter. Victory Capital Management Inc. now owns 15,436 shares of the company's stock valued at $700,000 after purchasing an additional 348 shares during the period. M&T Bank Corp increased its stake in shares of Ionis Pharmaceuticals by 7.8% in the fourth quarter. M&T Bank Corp now owns 5,188 shares of the company's stock valued at $263,000 after purchasing an additional 376 shares during the period. Finally, GAMMA Investing LLC acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 93.86% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IONS. Needham & Company LLC reiterated a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. Wolfe Research upgraded shares of Ionis Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $58.00 price objective on the stock in a research note on Wednesday, April 10th. StockNews.com upgraded shares of Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, February 24th. Finally, Oppenheimer raised their target price on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an "outperform" rating in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $57.67.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the completion of the sale, the executive vice president now owns 19,631 shares of the company's stock, valued at approximately $816,649.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.65% of the company's stock.

Ionis Pharmaceuticals Trading Up 0.7 %

Ionis Pharmaceuticals stock traded up $0.31 during midday trading on Monday, reaching $42.28. The stock had a trading volume of 928,265 shares, compared to its average volume of 1,115,770. The firm's fifty day simple moving average is $42.99 and its two-hundred day simple moving average is $46.96. Ionis Pharmaceuticals, Inc. has a twelve month low of $34.79 and a twelve month high of $54.44. The company has a debt-to-equity ratio of 3.18, a current ratio of 5.90 and a quick ratio of 5.83. The firm has a market cap of $6.16 billion, a price-to-earnings ratio of -16.52 and a beta of 0.41.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The firm had revenue of $325.00 million during the quarter, compared to analyst estimates of $176.01 million. During the same quarter last year, the business posted ($0.37) EPS. The company's revenue was up 113.8% on a year-over-year basis. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.